A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

Trial Profile

A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Triamcinolone (Primary) ; Triamcinolone
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Flexion Therapeutics
  • Most Recent Events

    • 08 Nov 2017 Results of a meta-analysis of two randomised trials (FX006-2014-006 and FX006-2014-008) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 02 Nov 2017 According to a Flexion Therapeutics media release, pooled analysis data of this and two other trials (see CT profiles 210815 and 243924) will be presented at the 2017 American College of Rheumatology (ACR) Annual Meeting.
    • 06 Oct 2017 According to a Flexion Therapeutics media release, the U.S. Food and Drug Administration (FDA) approved Zilretta (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection for osteoarthritis knee pain. Approval was based on data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top